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Abstract 
The primary objective of this study was to establish in vivo a correlation between equol production and 
number of bacteria able to perform the transformation. Secondary objective include the assessment of 
daidzein and its metabolites in plasma (0-99 h) and urine (0-96 h) after oral administration of 100 mg 
daidzein in soymilk. Healthy female volunteers were enrolled for their in vitro ability to convert 
slowly (n=6, 105-109 cell/ g wet faeces) or quickly (n=6, 1010-1012 cell/ g wet faeces) daidzein in 
equol. Plasma and urine samples were analysed by LC-MS/MS and UPLC-High Resolution-MS. Only 
for equol seemed to be a direct correlation between the number of transforming microorganisms and 
some parameters such as tmax and t1/2 (p=0.027). Peak serum concentration time, Cmax, AUC0-72h and t1/2 
for total equol (n=12) were 3610 h, 8978 nM, 2.41.7 (µmol x h/L) and 15.63.3 h, respectively. 
Equol metabolites were found only as glucuronide conjugates.     
 
 
 
Keywords  
Daidzein; Equol; pharmacokinetics; metabolism; human; mass spectrometry 
  
 2 
Introduction 
Soy isoflavones such as daidzein (DAI) and genistein have received attention for their 
potential prevention or treatment of estrogen- and androgen-mediated diseases (Travis et al., 
2009). This plant-based class of phytoestrogens seems also to demonstrate a prophylactic role 
in the onset of some cancers such as prostate (Lee et al., 2009), breast (Rimbach et al., 2008) 
and colon (Coxam, 2009), cardiovascular disease (Kokubo et al., 2007) and osteoporosis 
(Euhara, 2013). Moreover, there are some data suggesting that soy isoflavones have beneficial 
effects on lipid homeostasis and glycemic control (Anderson et al.; 1993; Yang et al., 2004), 
and play a role in lowering blood concentrations of total cholesterol and LDL-cholesterol in 
human, limiting the development of atherosclerosis (Hodis et al., 2011) and inhibiting the 
transcriptional nuclear factor NF-kB, the COX2 and aromatase (Rice et al., 2006).  
     On the other hand, studies of soy isoflavones intake in experimental animals suggest 
possible adverse effects such as enhancement of reproductive organ cancer, antithyroid effects 
(Xiao  et al., 2014) and it seems correlated with lower sperm counts (Xia et al., 2013). 
Moreover, recent studies do not support the hypothesis that phytoestrogens prevent prostate or 
colorectal cancer (Bosland et al., 2013).  
     Metabolic investigations have observed a biphasic isoflavones appearance pattern in 
plasma and urine of humans after consumption of soy preparations, with two maximum 
concentrations at about two and six hours after intake (Franke et al., 2014). The time at which 
the first peak occurred (1-2 h) suggested that uptake occurred in the proximal small intestine 
(Walsh et al., 2007), particularly in the jejunum (Zubik and Meydani, 2003). The second peak 
at 4-6 h indicated that absorption took place in the large intestine and this suggested the 
involvement of the microflora. Thus, after ingestion, in the large intestine, anaerobic bacteria 
hydrolyse the glycosylated isoflavones to their respective aglycones and daidzein could be 
metabolized to dihydrodaidzein (DHD), O-desmethylangolensin (ODMA) and equol (EQU) 
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(Walsh et al., 2007) (Figure 1). To underline that in plasma and urine equol and ODMA are 
found as their S(-) and R(-) enantiomers, respectively, while there were both the enantiomers 
of the DHD. Once formed, these metabolites are absorbed and conjugated in the liver with 
glucuronic acid and/or sulphate (Shelnutt et al., 2000), which are then excreted predominantly 
in the urine (Shelnutt et al., 2000) (Figure 1). The conjugated forms of DAI, DHD, EQU and 
ODMA represent more than 90 and 95% of the plasmatic and urinary forms, respectively 
(Gardana et al., 2014).  
     Most of the isoflavones found in plasma and urine are present as glucuronides and in lower 
amount conjugated with sulfate (Shelnutt et al., 2000; Legette et al., 2014; Thomas et al., 
2001), which could exert various health effects as well. Daidzein sulfate conjugates, but not 
daidzein, inhibited sterol sulfatase, which is involved in the development of breast cancer in 
vitro (Wong and Keung, 1997).  
     To date, there is limited information on the conjugation profile of daidzein (Doerge et al., 
2000; Hosoda et al., 2011; Shelnutt et al., 2002; Zhang et al., 2003), and those relating to the 
equol are even less (Legette et al., 2014; Schwen et al., 2012; Redmon et al., 2016; Koh and 
Mitchell 2011). This is due to non-availability of reference standards and, until recently, to 
sensitive and specific analytical techniques. Therefore, it is generally determined the total 
amount of these compounds in biological fluids and tissues before and after hydrolysis with 
glucuronidase/sulphatase and the conjugated forms determined by difference.  
     In this research, we aim to explore the capabilities of the high-resolution mass 
spectrometry (HR-MS), in full-scan acquisition mode, in order to evaluate the equol 
conjugates forms present in plasma and urine samples after soymilk intake. Moreover, we 
found in vitro (Gardana et al., 2014) a possible direct correlation between the conversion rate 
of the DAI to ODMA and the number of bacteria that were able to perform the 
transformation. This correlation was found in vivo only for the time to reach the maximum 
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concentration but not for the other pharmacokinetic indexes evaluated. Thus, the purpose of 
this study was also to determine whether there was a correlation between EQU production and 
number of bacteria able to perform the transformation. 
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Materials and methods         
Chemicals 
Purchased chemicals included the standards daidzin, DAI, DHD, (R,S)-EQU and (R,S)-
ODMA from Plantech (Reading, UK). Sakuranetin (SAK), formononetin (4’-methyldaidzein) 
and quercetin-glucuronide were obtained from Extrasynthese (Genay, France). Type H5 -
glucuronidase/sulfatase from Helix pomatia was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Methanol, acetonitrile, sodium acetate and acetic acid were from Merck 
(Darmstadt, Germany). Water was obtained from a MilliQ apparatus (Millipore, Milford, 
MA). Soymilk from organic culture (NaturGreen Food, Murcia, E) was acquired in a local 
supermarket. Daidzein pure compound, approximately 95 mg, was dissolved in 100 mL of 
soymilk. 
 
Subject and study design 
In a previous work, the transformation of daidzein into DHD, EQU and ODMA was 
investigated in anaerobic batch cultures inoculated with mixed fecal bacteria from 90 healthy 
volunteers (Gardana et al., 2009). The results showed that in most subjects the number of 
microorganisms able to convert DAI in EQU were lesser than 109 cells/g wet faeces, and in 
few subjects the amount of equol-producing microbial populations were higher than 1010 
cells/g wet faeces. The latter belonged to the sub-group at high rate conversion, whereas the 
other subjects had demonstrated slower equol-production in time-course experiments.  
     From the “equol-producer” subjects we have recruited six “fast equol producers” and six 
“slow equol producers” (aged=45-64 years, BMI=23.4±3.3 Kg/m2). The number of faecal 
microorganisms able to convert DAI to EQU was evaluated by the Most Probable Number 
method as described by Gardana et al. (2009).  
     They were not taking any supplement, drug or medication. Informal, written consent was 
obtained from each participant and the local ethical committee approved the protocol. 
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Volunteers refrained from consuming food and beverages containing isoflavones 7 days prior 
to the study and 1 week after soymilk intake. On the day of the experiment, subjects were 
confined to the laboratory and between 6:00 and 6:30 a.m. the fasted volunteers received 100 
mL of soymilk, containing 100 mg of DAI and 4 mg of daidzin, with jam (25 g) and bread (50 
g). After dinner, the volunteers were allowed to leave the laboratory, returning the next four 
days for the blood and urine sampling.  
     Blood samples were collected in tubes containing lithium-heparin at the following time 
points: 0, 3, 5, 7, 9, 11, 27, 36, 51, 60, 75, 84 and 99 h after the soymilk consumption. Urine 
was collected into plastic bottles in five fractions (0-24, 24-48, 48-72 and 72-96 h) stored at 4 
°C during the sampling period. The amount of urine in each fraction was measured, portioned 
in glass vials (1 mL) and frozen at -70 °C immediately after the participants had started to 
collect the next fraction.  
 
Method validation 
Calibration curves were constructed for each standard at five concentration levels and three 
independent determinations were performed at each concentration. LLOQ was determined by 
serial dilution of standard solutions and defined by the lowest injected inter-day concentration 
whose RSD% resulted to be <20% (Shah et al., 2000). LOD was defined by the lowest 
concentration that the assay can differentiate from background levels (S/N ratio > 3).  
     The accuracy (matrix effect) was evaluated according to a previously published paper 
(Gardana et al., 2007) using three sets of six standard lines (0.2 - 100 ng/mL). All the tests 
and LC-MS/MS analyses were carried out in triplicate and an internal standard (Sakuranetin) 
was used to correct the loss of analytes during sample preparation. Intra- and inter-day 
precision of the assay was verified by analyzing samples set 3 times on five consecutive days. 
     Repeatability was confirmed by evaluating standard deviations of the retention times and 
peak areas. 
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Determination of Daidzein and its glycosides in soymilk 
One mL of soymilk was extracted by 5 mL of methanol and the resulting solution sonicated 
for 10 min, centrifuged at 1000 x g for 10 min and the residue was extracted twice by 
methanol. The supernatants were put together, the volume set to 20 mL with methanol and the 
resulting solution filtered through a 0.2 m disk before injecting 5 L in the LC-DAD-MS 
system. The chromatographic system consisted of an Alliance 2695 (Waters, Milford, MA) 
equipped with a model 2998 (Waters) photodiode array detector and a triple quadrupole mass 
spectrometer mod. Quattromicro (Micromass, Beverly, MA).  
     A 3.5 m C18 Symmetry column (150x2.1 mm, Waters) was used for the separation, which 
was performed by means of a linear gradient elution (eluent A, 0.05% acetic acid; eluent B, 
acetonitrile) at a flow rate of 250 L/min. The column and the samples were maintained at 
30°C and 20°C, respectively. The gradient was as follows: from 10 to 25% B in 10 min, from 
25 to 35% B in 10 min and then from 35 to 55% B in 10 min. Chromatographic data were 
acquired in the 200-450 nm range and were integrated at 254 nm. Calibration curves were 
obtained from daidzin and daidzein stock solutions prepared by dissolving 20 mg of standard 
powder in 20 mL of methanol. They were measured in the range of 2-100 g/mL. 
     The mass spectrometer operated in full-scan mode in the range (m/z)- 200-1000 u. All data 
were acquired by Masslink 4.0 software (Micromass).  
 
Plasma and urine preparation 
Sample preparation for the quantitative analysis 
Heparinized plasma (200 L) was incubated with 100 L glucuronidase/sulphatase (1 U/L) 
and 50 L I.S. (Sakuranetin, 50 ng/mL) in 0.1 mol/L CH3COONa buffer (pH 5.2) at 37°C for 
18 h. The reaction mixture was extracted with 500 L ethylacetate, vortexed and centrifuged 
at 1000 x g for 1 min. The supernatant (350 L) was dried under N2 and the residue dissolved 
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in 100 l methanol. A solution of quercetin-glucuronide (50 ng/mL) was incubated with 100 
U glucuronidase/sulphatase and I.S. to assess the enzymatic activity. 
     To evaluate non-conjugated analytes, a plasma sample (200 L) was incubated with 50 L 
I.S. and 100 L of 0.1 mol/L CH3COONa buffer (pH 5.2) for 18 h at 37°C. The reaction 
mixture was then treated as described above.  
    Urine sample (200 L) was incubated with 200 L glucuronidase/sulphatase (1 U/L) and 
50 L I.S. (Sakuranetin, 50 ng/mL) in 0.1 mol/L CH3COONa buffer (pH 5.2) at 37°C for 18 
h. The reaction mixture was extracted with 800 L ethylacetate, vortexed and centrifuged at 
1000 x g for 1 min. The supernatant (600 L) was dried under N2 and the residue dissolved in 
1 mL methanol. To evaluate non-conjugated analytes, a urine sample (200 L) was incubated 
with 50 L I.S. and 200 L of 0.1 mol/L CH3COONa buffer (pH 5.2) for 18 h at 37°C. The 
reaction mixture was then treated as described above. 
 
Sample preparation for the qualitative analysis 
For the determination of the equol conjugates in plasma, phospholipid and protein was 
removed by Phree tube (Phenomenex, Torrence, CA). Briefly, 200 L of plasma was placed 
into a Phree tube and then 600 L acetonitrile was pipetted directly into the plasma sample. 
The reaction mixture was vortexed and after 1 min the tube was loaded onto a manifold 
(Waters), to which was applied a negative pressure. The eluate was collected and analyzed by 
UPLC-HR-MS.    
    For the analysis of equol conjugates in urine, 200 L of sample was diluted to 1 mL by a 
solution of 0.1% CH3COOH in water and the resulting solution centrifuged at 1000 x g for 2 
min before injecting 5 µL in the UPLC-HR-MS system.   
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LC-ESI-MS/MS analysis of DAI and its metabolites plasma and urine 
The chromatographic system consisted of an HPLC mod. Alliance 2695 (Waters) coupled to a 
triple quadrupole mass spectrometer mod. Quattromicro (Micromass). A 3.5 m C18 
Symmetry Shield column (150x2.1 mm, Waters) was used for the separation, which was 
performed by means of a linear gradient elution (eluent A, 0.02% CH3COOH; eluent B, 
acetonitrile) at a flow rate of 250 L/min. The gradient was as follows: 25% B for 5 min, 
from 25 to 50% B in 0.2 min and then 50% B for 10 min. The column was maintained at 30°C 
and 5l injected in LC-MS/MS system. The capillary voltage was set to 3.0 kV, the cone 
voltage and the collision energy was specific for each compound. The source temperature was 
130°C, the desolvating temperature was 350°C and argon was used at 2.0x10-3 mbar to 
improve fragmentation in the collision cell.  
     Analytes were determined in multiple reaction monitoring mode (MRM) and data were 
acquired by Masslinx 4.0 with Quan-Optimize option for fragmentation study. The mass 
spectrometer operated in ESI negative mode and the fragmentation transitions were the 
following: (m/z)
-
 253 to 91 for DAI, 255 to 149 for DHD,  241 to 119, 121, 135 for EQU, 257 
to 109, 135 for ODMA and 285 to 165, 119 for SAK (I.S.). A dwell time of 0.2 s for 
transition was used.  
     The determinations were carried out in triplicate. Calibration curves were obtained from 
DAI, DHD, EQU, ODMA and I.S. stock solutions prepared by dissolving 20 mg of standard 
powder in 100 mL methanol. They were measured in the range of 5-100 ng/mL and for DAI it 
was prepared an additional calibration curve in the range 100-1000 ng/mL. 
 
UPLC-HR-MS analysis of the EQU-conjugates in plasma and urine 
The UPLC-HR-MS analysis was carried out on an UPLC model Acquity (Waters) coupled 
with a high-resolution Fourier Transform mass spectrometer (HR-FT-MS) model Exactive 
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(Thermo Scientific, San Jose, CA, USA) equipped with an HESI-II probe for electrospray 
ionization and a collision cell (HCD). The operative conditions were: spray voltage -3.0 kV, 
sheath gas flow-rate 55, auxiliary gas flow-rate 10, capillary temperature 275 °C,  capillary -
37.5 V, tube lens -125 V, Skimmer -26 V, and heather temperature 130 °C. Five μL was 
injected on a 1.7 μm BEH Shield C18 column (150×2.1 mm, Waters) kept at 50 °C. The 
eluents were 0.02% acetic acid in MilliQ-treated water (solvent A) and acetonitrile (solvent 
B). The UPLC separation was performed by the following linear elution gradient: 5 to 35% of 
solvent B in 10 min and then from 35 to 80 % in 10 min at a flow-rate of 0.45 mL/min.  
     The identification of the conjugated metabolites was performed in full-scan mode in the 
range (m/z)- 80-1000 u, using an isolation window of ±2 ppm. The AGC target, injection time, 
mass resolution and energy in the collision cell were 1x106, 100 ms, 50 K and 30 V, 
respectively. The MS data were processed using Xcalibur software (Thermo Scientific). The 
peak identity was ascertained by evaluation of both the accurate mass that the fragments 
obtained in the collision cell. 
 
Statistical analysis 
Statistical analyses were performed with the STATISTICA software (Statsoft Inc, Tulsa, OK, 
USA). A one-way repeated measure analysis of variance (ANOVA) with the time as the 
independent factor was used. The kinetic indexes and the amount excreted by urine have been 
expressed as mean±s.d. The terminal half-life was calculated as 0.6935/K. The area under the 
plasma concentration time curve (AUC0-t) was calculated using the linear trapezoidal rule in 
the range 0-51 h (DAI) or 0-72 h (DHD, EQU and ODMA).  
     The log10-transformed urinary [EQU]/[DAI] ratio was used to define in vivo equol 
producer status (Setchell and Cole, 2006). Each analyte was analyzed separately for each 
kinetic parameter for assessing if there were any significant differences between slow- and 
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quick-equol producers using the Wilcoxon matched pairs test. P values < 0.05 were 
considered significant.  
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Results 
Equol production in vitro 
The accuracy of the extraction for EQU from spiked sterilised faecal samples was 96-103 and 
93-105% for intra-day and inter-day assays, respectively. The controls did not produce 
compounds overlapping with EQU. No changes were detected in EQU amount after 96 h 
incubation with bacteria from faeces of EQU-producing volunteers.  
     The comparison of the different time-course experiments allowed identification of a sub-
group of EQU-producers able to convert 50% of DAI to EQU in about 6 h (Supplemental 1).     
In these volunteers, the number of microorganisms able to convert DAI in EQU was in the 
range 1010-1012 cells/g wet faeces. These volunteers belonged to the sub-group at high 
conversion rate.  
     The other EQU-producers reached the highest concentration of EQU between 20 and 30 h 
(Supplemental 1) and 50% of DAI was converted to EQU after about 12-16 h of incubation. 
These volunteers had a number of microorganisms in the range 105-109 cells/g wet faeces, and 
therefore belonging to a sub-group at lower conversion rate. 
 
Quantitative determination of daidzein and its metabolites in plasma and urine 
During the direct infusion of DAI, DHD, ODMA, EQU and IS solutions in the mass 
spectrometer, all were easily deprotonated in the negative ionization mode, providing ions 
with appropriate intensity except for the EQU for which the signal intensity was lower by 
about 50% compared to that of daidzein.  
     Thus, ESI in negative mode was chosen for the qualitative and quantitative analysis of all 
the analytes and IS in human plasma and urine. The [M-H]- ion was then used as the precursor 
to obtain typical product ion spectra. The MRM fragmentation transitions were (m/z)
-
 
25391, 255149, 257109 and 285 165 u for DAI, DHD, ODMA and IS, respectively.  
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     Regarding EQU, to increase the specificity of the analysis three product ions were chosen 
such as 241119, 24193 and 241135 u (Supplemental 2). Figure 2 shows an example of 
DAI, DHD, EQU, ODMA and IS peaks detected by LC-MS/MS in an enzymatically 
hydrolysed plasma sample obtained 27 h after soy milk intake.  
     The recovery of the extraction for DAI, DHD, EQU, ODMA and IS from spiked plasma 
samples was 943, 874, 913, 883 and 954%, respectively. The precision of the method 
was tested by both intra-day (n=6) and inter-day (5 days, n=6) reproducibility, and the 
coefficient of variation was below 11%. The DAI, DHD, EQU and ODMA concentrations 
were calculated by external standardisation from calibration curves and their levels in plasma 
and urine were evaluated before and after the enzymatic hydrolysis.  
    The conjugated forms of these analytes represented more than 95% of the plasmatic and 
urinary forms. None of the subjects had detectable amounts of DAI or its metabolites at 
baseline. All subjects absorbed DAI and EQU, while DHD and ODMA were found in nine 
and seven subjects, respectively.  
    Regarding the evaluated pharmacokinetic parameters, great inter-individual differences 
were detected. The Cmax of EQU was reached in 36±10 h (n=12) after the DAI ingestion and 
only in one subject it was found after 60 h. Table 1 reports the values of the kinetics indexes 
calculated from the DAI, DHD, EQU and ODMA plasma levels. The half-life (t1/2) for DAI, 
DHD, EQU and ODMA was about 9, 7, 16 and 9 h, respectively. The amount of the analytes 
excreted in urine following the intake of 100 mL of soymilk containing 100 mg of DAI is 
reported in table 2. 
 
  
 
 
 14 
Identification of Equol-conjugates in plasma and urine 
The metabolites of equol produced in vivo by human were determined by UPLC coupled to 
high resolution mass spectrometry detector. In figure 3 was reported the extracted ions, 
contained in a sample of urine (24-48h), with (m/z)- 417.1185, 321.0438, and 241.0870, 
corresponding to EQU-glucuronide, EQU-sulfate and EQU, respectively. The ions 
corresponding to equol (Fig. 3, peak A1 and A2) were obtained after fragmentation in the 
collision cell, and were used to confirm the identity of the equol-conjugates.  
     In this regard, the EQU-glucuronide (Fig. 3, peak B1 and B2) gave the product ions with 
(m/z)- 241.0865, corresponding to EQU, whilst EQU-sulfate (Fig. 3, peak C) did not. This 
could be due to the lower amount of EQU-sulfate, or it may not be EQU-sulfate. The latter 
hypothesis seems supported by the absence, after fragmentation in the collision cell, of the 
ions with (m/z)- 96.9601 or 80.9652 corresponding to HSO4
- and HSO3
-, respectively. Thus, it 
seems that in urine and plasma glucuronides were the major EQU-metabolite. Conversely, 
EQU and its other conjugates such as disulfates, diglucuronides, sulfate-glucuronides or 
methylated were not detected. 
     In the urine, a major glucuronide peak was found for equol (Fig. 3, peak B2) and a second 
glucuronide peak was present in all subjects in much lower quantities (Fig. 3, peak B1). The 
results obtained do not allow defining the position of the glucuronic acid in the equol 
molecule. At this regard, Schwen et al. (2012) suggested that the major metabolite of the EQU 
in rat plasma and urine was the 4'-glucuronide conjugate, with lesser amounts of the 7-sulfate 
conjugate, and the 4'-glucuronide-7-sulfate diconjugate. On the contrary, Clarke et al. (2002) 
identified in human urine, by authentic standard, EQU-7-glucuronide, EQU-4’-glucuronide 
and EQU-4’-glucuronide and the main peak was related to the 7-glucuronide. Redmon et al. 
(2016) reported that in dog, cat and human the 7-OH glucuronide was the major phase II 
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metabolite of the EQU.      Thus, based on these reported data we suppose that the main EQU-
glucuronide (Fig. 3, peak B2) found in plasma and urine was the 7-glucuronide.  
 
Discussion 
To the best of our knowledge, this is the first paper reporting the in vivo correlation between 
production rate of equol and the number of bacteria able to metabolise daidzein.  
     Among the twelve EQU-producing volunteers, six were able to convert 50% of DAI to 
EQU within about 6 hours of fermentation, while the other six EQU-producers reached the 
same level within about 12-14 hours. The different rates of formation seem to depend on the 
number of bacterial able to metabolise DAI to EQU. Indeed, in the faster EQU-producers, the 
number of microorganisms able to convert DAI in EQU was 1010 (n=2), 1011 (n=3) and 1012 
(n=1) cells/g wet faeces. These volunteers belonged to the sub-group with the higher rate of 
conversion. For other EQU-producers, the bacterial populations were 105 (n=1), 107 (n=4) and 
109 (n=1) cells/g wet faeces. These volunteers, who demonstrated slower EQU production in 
time-course experiments, belonged to the sub-group with the lower rate of conversion. Thus, 
it seems that the different rate of EQU production could be related to inter-individual 
differences in the number of EQU-producing microorganisms.  
     After 24 h of incubation, approximately 50% of the initial DAI was converted to EQU and 
once formed it was stable over 96 h. On the other hand, a percentage of DAI (40-50%) 
disappeared without the production of known metabolites. Thus, as already reported for the 
degradation of the DAI to ODMA (Gardana et al., 2014), the stoichiometric assessments 
suggest that the DAI degradation pathway responsible for forming EQU is not yet fully 
identified.  
     Equol was detected in the plasma and urine of all the subjects after enzymatic hydrolysis 
by glucuronidase/sulphatase. The kinetic data show that all healthy EQU-producers absorb 
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DAI rapidly and the time taken to attain peak plasma concentrations after ingestion is about 8 
h. At the contrary, slow- and high-EQU producers reach maximum plasma concentrations of 
EQU at about 45 and 34 h, respectively. At these times, the mean maximum plasma 
concentration (Cmax) of DAI, DHD and EQU was about 2.9 M, 0.1 M and 0.09 M, 
respectively. Thus, DAI Cmax was about 30-times higher than that of EQU. For the latter, the 
plasma profiles showed that there is a time lag in its appearance and that, after a single DAI 
ingestion, it takes at least 9-11 h before EQU appears in plasma. This observation is 
consistent with a colonic origin for its formation. In particular, our data suggest a direct 
correlation between t1/2, the conversion rate of the DAI to EQU and the number of bacteria 
that are able to perform the transformation. In fact, the t1/2 and tmax was 13 and 18 h and 45 
and 34 h for the subjects with lower and higher conversion rates, respectively.  
     One volunteer belonging to the subgroup with the lower rate conversion had tmax of 60 h, 
which was significantly different to that of other subjects of the same sub-group. At this 
regard, it should be highlighted that the latter had lowest number of microorganisms (105 
cells/g wet faeces) able to convert DAI to EQU. It was therefore possible that this subject was 
not an EQU-producer. To define the EQU-producer status, Setchell et al. (2006) suggest using 
the urinary log10 ([EQU]/[DAI]) ratio. In this way, values higher than -1.75 define equol 
producer status. Thus, we have calculated the urinary log10 ([EQU]/[DAI]) ratio and for the 
subject with the lowest number of transforming bacteria the value was -2.5, suggesting that 
was not an EQU-producer. On the contrary, the other subjects had a value higher than -1.3 
suggesting that they were EQU-producer.  
     The evaluation of the transforming bacteria could be an easy and non-invasive 
measurement to determine whether a subject is EQU-producer or not. Thus, it should be 
assessed the minimum number of transforming bacteria that determines the state of EQU-
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producer. Regarding Cmax and AUC, it seems that there is no correlation between these 
parameters and the number of bacteria able to produce EQU.  
     Most DAI is excreted into the urine within the first 24 h, with a high individual variability, 
ranging from 11 to 45% of the ingested amount. This finding is in agreement with Chang et 
al. (2013), which found a daidzein urinary excretion within 24 h in the range of 43-60%. 
Thus, the recovery of DAI in urine was low, also considering that the excretion of DHD and 
EQU produced by catabolism of DAI did not account for more than 10% of the dose 
ingested.  
    Bayer et al. (2001) reported that in rat 85±24% of the orally administered daidzein was 
excreted unchanged with feces and only approximately 9% was recovered in urine, in part as 
parent compound and as conjugates. At the contrary, Watanabe et al. (1998) reported that in 
human about 4.6 and 36% of the DAI were excreted in the feces and urine, respectively. 
Moreover, the authors reported that the total amounts of DAI recovered in urine and feces 
were about 55% of the ingested dose. These last data are in good agreement with our results 
and seem suggest that approximately 50% of the daidzein disappeared without being 
associated to the appearance of known metabolites.   
      Glucuronide peaks on the chromatogram were identified by accurate mass and product 
ions determination. In the urine of all the subjects, a major glucuronide peak was identified 
for equol, which was tentatively identified as the 7-O-glucuronide according to Clarke et al. 
(2002). In addition, a second glucuronide peak present in much lower quantities and eluting 
shortly before the EQU-7-O-glc peak was found, and it was tentatively identified as EQU-4’-
O-glucuronide.  
     It should be noted that a peak with molecular formula corresponding to EQU-sulfate (Fig. 
3, peak C) was detected in urine in some sample but, after fragmentation, the product ions 
related to EQU were not found. Thus, the peak with (m/z)- 321.0438 (Fig. 3, peak C) was not 
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considered EQU-sulfate. Regarding plasma, EQU-7-glucuronide was the only metabolite 
found, and EQU pharmacokinetics studies in human and animals such as pig, rat, dog, horse 
and monkey show similar metabolism (Redmon et al., 2016). 
     On the contrary, the deprotonated ions corresponding to possible metabolites of the EQU, 
such as -sulfate-methylated, -diglucuronide, -disulfate and -methylated were not detected. 
This is not in agreement with several authors that reported the presence of EQU-sulfate in 
urine and plasma sample (Shelnutt et al., 2002; Legette et al., 2014).  
     The first appearance of EQU-glucuronides in plasma occurred around 9-11 h after soymilk 
intake, and their concentration peaked around 40 h. The late appearance was due to time 
required for bacterial conversion of DAI to EQU in the large intestine. These findings are in 
agreement with those reported in literature (Legette et al., 2014). Moreover, data obtained in 
the range 27-51 h increase the knowledge concerning plasma concentrations and kinetic of the 
EQU-conjugates.   
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Legends to the figures 
 
Figure 1. Degradation of the daidzein (DAI) to racemic dihydrodaidzein (RS-DHD), R(-)-O-
desmethylangolensin [R(-)-ODMA) and S(-)-equol [S(-)-EQU] by intestinal bacteria and 
subsequent conjugation of the EQU with sulfate or glucuronic acid by hepatocytes. 
 
Figure 2. Typical LC-MS/MS chromatogram (MRM mode) of a plasma sample obtained 27 h 
after soymilk intake. 1: DAI (m/z)
-
 25391, 2: DHD 255149,  3: EQU, (a) 241119, (b) 
241121, (c) 241135, 4: ODMA 257109, 5: SAK (IS) 285 165 u. 
 
Figure 3. Chromatograms relative to a urine sample collected in the range 24-48 h after 
soymilk intake containing about 100 mg of daidzein. A1, A2: EQU (m/z)- 241.0870 obtained 
after fragmentation at 30 V in the collision cell. B1, B2: EQU-glucuronides (m/z)- 417.1191, 
C: EQU-sulfate (m/z)- 321.0438 u. The peaks B1, B2 and C were obtained in scan mode 
without fragmentation (HCD off).   
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  Table 1. Plasma kinetic indexes in 12 healthy volunteers for Daidzein and its metabolites after ingestion of about 100 mg daidzein in soy milk. 
 
                
  tmax (h) Cmax (µM or nM) AUC (µmol x h / L)   t½ (h) 
Analyte S H S H S H S H 
t-DAI 8.0±1.7 7.0±2.6 2.8±1.2 3.0±1.1 45.1±15.6 41.0±14.3 12.4±4.8 9.2±4.7 
t-DHD 27.0±0.0 17.4±10.4 66.5±65.8 117.0±82.1 1.8±1.9 2.1±1.3 5.2±3.4 6.5±3.4 
t-EQU 45.0±6.6a 34.5±12.7a 81.1±72.7 87.2±71.9 2.2±1.5 2.3±1.6 12.8±1.6b 18.4.4±1.7b 
t-ODMA 33.0±12.0 28.1±11.7 84.4±78.9 66.9±57.2 2.2±2.1 1.7±1.5 9.9±1.9 8.7±2.8 
 
t-DAI, total Daidzein; t-DHD, total Dihydrodaidzein; t-EQU, total Equol; t-ODMA, total O-Desmethylangolensin. 
S, Slow EQU producer (n=6); H, Quick EQU producer (n=6).  
Values with the same letters within the same line are significantly different (P < 0.05). tmax: p=0.027, t1/2: p=0.027 
tmax,  time taken to reach peak concentration; Cmax, peak concentration (µM for DAI, nM for DHD, EQU and ODMA); AUC area under the curve 
(0-51 h for DAI, 0-72 h for DHD, EQU and ODMA); t1/2, terminal half-life.  
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Table 2. Urinary excretion (mg, mean±s.d.)# of daidzein and its metabolites after 
             ingestion of about 100 mg daidzein in soymilk. 
          
Time (h) total DAI total DHD total ODMA total EQU 
Basal 0.0±0.0a 0.0±0.0a 0.0±0.0a 0.0±0.0a 
0-24 20.6±12.1b 2.0±2.5a 1.1±1.0a 1.0±0.9b 
24-48 4.0±2.7c 1.2±0.6a 1.3±1.1a 2.4±2.1c 
48-72 1.7±4.6c 0.0±0.1a 0.2±0.3a 0.6±0.5ab 
72-96 0.0±0.0 a 0.0±0.0a 0.0±0.0a 0.0±0.0a 
 Total 26.2±10.3 3.2±2.5 2.6±2.1 4.0±3.3 
      
# No significant difference was detected between slow and quick EQU producers (P < 0.05).  
Means between groups not having the same letters were statistically different.   
Effect of time was significant by ANOVA for DAI and EQU (p< 0.001).  
DAI: found in all subjects in the 0-24 and 24-48 h sample and in three volunteers also 
detected in the 48-72 h sample.  
DHD: not found in one subject belonging to the “slow EQU-producers” sub-class.  
ODMA: not found in two subjects. After 72 h was present in the urine of five subjects.  
EQU: found in all subjects in the 24 and 48 h sample and detected in eleven volunteers after 
72 h. In one subject, the log ([EQU]/[DAI]) was -2.5, suggesting that was not an equol-
producer. 
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Supplementary 1 
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Slower EQU-producers 
 
 
Y value (Percent) ≡ Equol percentage than expected value 
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Supplementary 2 
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Equol fragmentation pattern at 10, (A), 15 (B) and 20 eV 
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Supplementary 3 
 
 
Extracted ions at m/z 417.1185 u (A), contained in a sample of urine, corresponding to EQU-
glucuronide (error 1.4 ppm). In the fragmentation spectra (B) of the EQU-glucuronides (see 
Fig. 3, peak B1 and B2), obtained by a collision energy of 30 V, the main product ion had m/z 
241.0865 u (error 2.1 ppm), which correspond to EQU. The fragmentation pattern (B) show 
the loss of the glucuronic moiety (-176.0320 u, error 0.6 ppm).   
 
B 
A 
- 176.0320 
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